Table 1.
Baseline characteristic of study populations
| Variable | Abexol-tablets (n = 50) | Abexol-suspension (n = 50) | Total (n = 100) |
|---|---|---|---|
| Age (yr) | 51.6 ± 14.6 | 51.7 ± 13.5 | 51.6 ± 14.0 |
| Body mass index (kg/m2) | 25.7 ± 5.3 | 25.6 ± 4.6 | 25.7 ± 4.9 |
| Sex | |||
| Female | 38 (76.0) | 32 (64.0) | 70 (70.0) |
| Male | 12 (24.0) | 18 (36.0) | 30 (30.0) |
| Personal history | |||
| Arterial hypertension | 19 (38.0) | 20 (40.0) | 39 (39.0) |
| Overweight (25–30 kg/m2) | 13 (26.0) | 16 (32.0) | 29 (29.0) |
| Obesity (≥ 30 kg/m2) | 11 (22.0) | 8 (16.0) | 19 (19.0) |
| Smoking | 12 (24.0) | 5 (10.0) | 17 (17.0) |
| Diabetes mellitus | 3 (6.0) | 2 (4.0) | 5 (5.0) |
| Hypercholesterolemia | 4 (8.0) | 1 (2.0) | 5 (5.0) |
| Coronary disease | 1 (2.0) | 1 (2.0) | 2 (2.0) |
| Family history | |||
| Gastrointestinal cancer | 7 (14.0) | 10 (20.0) | 17 (17.0) |
| CM | |||
| Patients consuming CM | 28 (56.0) | 30 (60.0) | 58 (58.0) |
| IACE | 13 (26.0) | 13 (26.0) | 26 (26.0) |
| Diuretics | 12 (24.0) | 10 (20.0) | 22 (22.0) |
| β-blockers | 5 (10.0) | 5 (10.0) | 10 (10.0) |
| Calcium antagonists | 4 (8.0) | 2 (4.0) | 6 (6.0) |
| Antiplatelets drugs | 2 (4.0) | 3 (6.0) | 5 (5.0) |
| Antiallergic | 1 (2.0) | 4 (8.0) | 5 (5.0) |
| Lipid lowering drugs | 4 (8.0) | 1 (2.0) | 5 (5.0) |
| Oral hypoglycemic drugs | 1 (2.0) | 2 (4.0) | 3 (3.0) |
| Antiasthmatic | 1 (2.0) | 1 (2.0) | 2 (2.0) |
| Antidepressants | 2 (4.0) | 0 (0.0) | 2 (2.0) |
Values are presented as mean ± standard deviation or number (%).
CM, concomitant medications; IACE, inhibitors of angiotensin converting enzyme.
The table includes only those consumed by ≥ 2 patients.
No significant between group differences were found (Student test, χ2 test).